AbbVie (NYSE: ABBV) – Mirvetuximab soravtansine PSOC clinical results were the highlight of the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico. AbbVie announced late-breaking data from the Phase 2 IMGN853-0420 trial, demonstrating high response rates for ELAHERE® (mirvetuximab soravtansine-gynx) in combination with carboplatin for patients with recurrent platinum-sensitive ovarian cancer (PSOC).
The trial evaluated a novel “induction-to-maintenance” approach, combining the first-in-class antibody-drug conjugate (ADC) with standard chemotherapy to address a significant unmet need in the platinum-sensitive ovarian cancer treatment landscape.
Phase 2 IMGN853-0420 Study Design and Efficacy
The multicenter, open-label study enrolled 125 patients with folate receptor alpha (FRα)-positive PSOC who had received one prior line of platinum-based therapy. The treatment regimen consisted of mirvetuximab soravtansine-gynx plus carboplatin every three weeks for up to eight cycles, followed by mirvetuximab soravtansine monotherapy for those who did not progress.
According to Dr. Gottfried E. Konecny, primary investigator and Professor of Medicine at UCLA, the Mirvetuximab soravtansine PSOC data support a new paradigm where ADCs are integrated earlier into the treatment of recurrent disease.
Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment
| Patient Subgroup | Confirmed ORR | 95% Confidence Interval |
| FRα High (≥50% Expression) | 62.7% | 52.6% – 72.1% |
| Overall Population (FRα ≥25%) | 62.4% | 53.3% – 70.9% |
| Prior PARP Inhibitor Exposure | 63.9% | N/A |
| Transitioned to Monotherapy | 68.0% | 59.1% – 76.1% |
Secondary Outcomes and Durability
Beyond the primary endpoint, the data showed a median Duration of Response (mDOR) of 11.2 months across the overall population. Notably, 81% of patients (101 out of 125) successfully completed the combination phase and transitioned to monotherapy, showcasing the feasibility of this long-term treatment strategy.
Safety Profile of Mirvetuximab Soravtansine PSOC Therapy
The safety results for the Mirvetuximab soravtansine PSOC combination were consistent with the known profiles of both agents. While the efficacy was robust, clinicians noted the importance of monitoring for ocular toxicities, a known side effect of the ADC.
| Adverse Event | All Grades (%) | Grade 3 or Higher (%) |
| Neutropenia | ~35% | 15% |
| Blurred Vision | ~42% | 10% |
| Thrombocytopenia | ~28% | 10% |
| Nausea | ~32% | <2% |
Read More: AbbVie Enters Into the Obesity Drug Market With a License Agreement
Ocular events, including corneal changes, were reported but were reversible in over 90% of cases with proper management and dose modifications. For more on managing side effects, clinicians can refer to the official ELAHERE safety guide.
Future Outlook for AbbVie in Oncology
The success of the IMGN853-0420 trial marks another milestone in AbbVie’s expansion of its oncology pipeline. By moving ELAHERE into earlier lines of therapy like PSOC, AbbVie aims to redefine the standard of care for FRα-positive cancers.
This data follows the previous FDA full approval of ELAHERE for platinum-resistant ovarian cancer (PROC) in 2024. The company is now looking toward Phase 3 trials to confirm these results and potentially secure a label expansion for Mirvetuximab soravtansine PSOC.
